# US 2026/0061013 A1 · Synthetic oncolytic lnp-replicon rna and uses for cancer immunotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061013 A1
- Document ID: US20260061013A1
- Status: Published application
- Kind: A1
- Application number: 19/264,067
- Filed: 2025-07-09
- Published: 2026-03-05
- Earliest claimed: 2019-03-08
- Assignees: Massachusetts Institute of Technology; Ohio State Innovation Foundation
- Applicants: Massachusetts Institute of Technology; Ohio State Innovation Foundation
- Inventors: Darrell J. Irvine; Karl Dane Wittrup; Ron Weiss; Yingzhong Li; Noor Momin; Yizhou Dong
- Web page: https://patentgrep.com/patent/US20260061013A1

## CPC

- A61K 35/768: Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- C12N 15/86: Viral vectors
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7105: Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A61P 35/00: Antineoplastic agents
- C07K 14/5434: {IL-12}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 2770/36121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/36132: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.

## Claims

### Claim 1

A synthetic oncolytic virus, comprising:
(i) a lipid nanoparticle comprising one or more types of lipid; and
(ii) a self-amplifying replicon RNA comprising a sequence that encodes an interleukin (IL)-12 molecule;
wherein the lipid nanoparticle is capable of triggering immunogenic cell death, and
wherein the IL-12 molecule is expressed by the self-amplifying replicon RNA.

### Claim 2 (depends on 1)

The synthetic oncolytic virus of claim 1, wherein the one or more types of lipid comprises a cationic lipid.

### Claim 3 (depends on 2)

The synthetic oncolytic virus of claim 2, wherein the cationic lipid is N1,N3,N5-tris(3-(didodecylamino) propyl)benzene-1,3,5-tricarboxamide (TT3).

### Claim 4 (depends on 2)

The synthetic oncolytic virus of claim 2, wherein the lipid nanoparticle comprises TT3, 1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), cholesterol, and C14-PEG2000.5.

### Claim 5 (depends on 1)

The synthetic oncolytic virus of claim 1, wherein the self-amplifying replicon RNA is derived from an alphavirus or a hepatitis C virus.

### Claim 6 (depends on 5)

The synthetic oncolytic virus of claim 5, wherein the alphavirus is Venezuela Equine Encephalitis virus, Semliki Forest virus, or Sindbis virus.

### Claim 7 (depends on 1)

The synthetic oncolytic virus of claim 1, wherein the sequence that encodes the IL-12 molecule is located in a subgenomic region of the self-amplifying replicon RNA.

### Claim 8 (depends on 1)

The synthetic oncolytic virus of claim 1, wherein the self-amplifying replicon RNA comprises a nucleotide sequence that is at least 90% identical to SEQ ID NO: 1.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

The synthetic oncolytic virus of claim 8, wherein the replicon RNA comprises a point mutation of G3936C and/or A4758G of SEQ ID NO: 1.

### Claim at position 11

-12. (canceled)

### Claim 13 (depends on 1)

The synthetic oncolytic virus of claim 1, wherein the IL-12 molecule is IL-12, an IL-12 subunit, or a mutant IL-12 molecule that retains the immunomodulatory function.

### Claim 14 (depends on 13)

The synthetic oncolytic virus of claim 13, wherein the IL-12 molecule comprises IL-12α and/or IL-12β subunits.

### Claim 15 (depends on 1)

The synthetic oncolytic virus of claim 1, wherein the lipid nanoparticle has a diameter of about 100-120 nm, and wherein the lipid nanoparticle has a zeta potential of about 3-6 mv.

### Claim at position 15

-17. (canceled)

### Claim 18 (depends on 1)

A pharmaceutical composition, comprising:
the synthetic oncolytic virus of claim 1 and a pharmaceutically acceptable carrier.

### Claim 19

(canceled)

### Claim 20 (depends on 1)

A method for treating cancer in a subject in need thereof, comprising:
administering to the subject an effective amount of the synthetic oncolytic virus of claim 1.

### Claim 21 (depends on 20)

The method of claim 20, wherein the subject is a human patient having or suspected of having a cancer.

### Claim 22 (depends on 21)

The method of claim 21, wherein the human patient has a cancer selected from the group consisting of melanoma, breast cancer and colon cancer.

### Claim 23 (depends on 20)

The method of claim 20, wherein the synthetic oncolytic virus is administered to the subject in a single dose.

### Claim 24 (depends on 20)

The method of claim 20, wherein the synthetic oncolytic virus is administered to the subject by intratumoral injection, intramuscular injection, subcutaneous injection, or intravenous injection.

### Claim 25 (depends on 1)

A method of producing a composition comprising the synthetic oncolytic virus of claim 1, the method comprising loading the self-amplifying replicon RNA in the lipid nanoparticle.

### Claim 26 (depends on 25)

A lipid nanoparticle comprising an IL-12 molecule produced by the method of claim 25.
